KX2-391 dihydrochloride: Dual Src Kinase and Tubulin Inhibitor for Cancer and Antiviral Research

Executive Summary: KX2-391 dihydrochloride (Tirbanibulin dihydrochloride, SKU A3535) inhibits Src kinase at nanomolar concentrations and disrupts tubulin polymerization by binding a unique site on the α-β tubulin heterodimer, requiring ≥80 nM for cellular effects. It is clinically validated for actinic keratosis and demonstrates suppression of hepatitis B virus (HBV) transcription via direct promoter targeting. Peer-reviewed benchmarks confirm potent downregulation of oncogenic proteins and upregulation of apoptosis markers in HPV(+) cell models (Moore et al., 2024). APExBIO supplies KX2-391 dihydrochloride as a solid for research, with defined solubility and storage parameters (product page).

Biological Rationale

KX2-391 dihydrochloride is a rationally designed small molecule combining two mechanisms: Src kinase inhibition and tubulin polymerization disruption. Src kinases are central to cell proliferation, migration, and survival in cancer. Tubulin polymerization is essential for mitotic spindle formation and cell division. Dual inhibition disrupts both signal transduction and cytoskeletal integrity, providing synergistic anticancer action (internal article). This duality also extends to antiviral effects, notably HBV and HPV-related oncogenesis, by targeting viral transcriptional regulation and host cell cycle machinery (Moore et al., 2024).

Mechanism of Action of KX2-391 dihydrochloride

KX2-391 dihydrochloride binds the substrate-binding site of Src kinase, inhibiting phosphorylation events in the canonical Src-MEK-ERK pathway. IC50 values are 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) for Src inhibition (product page). Unlike ATP-competitive inhibitors, KX2-391 targets a non-ATP site, reducing competitive escape. The compound also binds a novel pocket on the α-β tubulin heterodimer, requiring ≥80 nM for cellular inhibition of tubulin polymerization. This disrupts mitotic spindle assembly and leads to apoptosis. Additionally, KX2-391 suppresses HBV transcription by targeting the HBV precore promoter, with EC50 values of 0.14 μM (PXB cells) and 2.7 μM (HepG2-NTCP cells). It also blocks botulinum neurotoxin A (BoNT/A) activity at 10–40 μM by inhibiting SNAP-25 cleavage (internal analysis). Thus, KX2-391 integrates multi-pathway inhibition effective in cancer, virology, and neurobiology.

Evidence & Benchmarks

• KX2-391 dihydrochloride (Tirbanibulin) exhibits an IC50 of 31.49 nM for proliferation inhibition in HPV18(+) HeLa cells (Moore et al., 2024).
• It downregulates Src, phospho-Src, Ras, c-Raf, ERK1, phospho-ERK1, and phospho-ERK2, reducing oncogenic signaling in vitro (Fig. 3, Moore et al., 2024).
• Significant reduction of HPV E6 and E7 oncoprotein expression is observed, correlating with inhibition of the Src-MEK pathway (Moore et al., 2024).
• Apoptosis markers (cleaved PARP) are upregulated, while anti-apoptotic proteins (Mcl-1, Bcl-2) are downregulated in a dose-dependent manner (Moore et al., 2024).
• Oral dosing in mice (5–15 mg/kg qd/bid) and chimpanzees (1 mg/kg bid) achieves plasma levels for anti-HBV efficacy (product page).
• KX2-391 1% ointment is clinically approved for actinic keratosis (EU/US, 2020–2021) (Moore et al., 2024).
• Effective BoNT/A inhibition occurs at 10–40 μM by blocking SNAP-25 cleavage (product page).

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is used in research on cancer, virology (notably HBV and HPV), and neurotoxin biology. Its dual action allows for pathway-selective studies and combinatorial targeting. The compound is supplied by APExBIO (product page). For a deeper mechanistic exploration, see KX2-391 Dihydrochloride: A Dual-Mechanism Catalyst for New Benchmarks, which focuses on strategic deployment, whereas this article updates with 2024 clinical findings. KX2-391 is not a general cytotoxic agent; its effects are mediated through Src and tubulin pathways. It is not effective in pathways lacking Src or tubulin dependence. Topical application is validated for actinic keratosis, but systemic efficacy is context-dependent, requiring appropriate dosing and formulation. Earlier reviews (KX2-391 Dihydrochloride: Pathway-Selective Inhibition and Application) provide foundational insights, while this article extends to recent translational and clinical benchmarks.

Common Pitfalls or Misconceptions

• KX2-391 dihydrochloride is not broadly effective against all cancer types—activity depends on Src/tubulin pathway dependence.
• It does not act as a conventional tubulin poison; its binding site is novel and requires ≥80 nM for effect.
• Water insolubility requires dissolution in DMSO or ethanol for in vitro work.
• Not all observed clinical effects (e.g., HPV lesion regression) are fully replicated in all preclinical models.
• Systemic use for antiviral effects is not yet standard of care; current approvals are for topical use in actinic keratosis.

Workflow Integration & Parameters

KX2-391 dihydrochloride is supplied as a solid (SKU A3535) and should be stored at -20°C. It is soluble at ≥25.2 mg/mL in DMSO and ≥48.8 mg/mL in ethanol (with warming), but insoluble in water. Recommended in vitro concentrations are 0.013–10 μM for anticancer/anti-HBV studies, and 10–40 μM for anti-BoNT/A assays (product page). In vivo, oral dosing in mice is 5–15 mg/kg once or twice daily; in chimpanzees, 1 mg/kg bid. Clinically, topical 1% ointment and oral doses of 40–120 mg/day are reported. For optimal integration, see Scenario-Based Best Practices with KX2-391 dihydrochloride, which provides real-world assay scenarios; this article clarifies new dosing and mechanistic benchmarks.

Conclusion & Outlook

KX2-391 dihydrochloride is a validated dual-mechanism agent with potent, pathway-selective inhibition of Src kinase and tubulin polymerization. Its clinical and preclinical track record spans oncology, antiviral research, and neurotoxin studies. Ongoing research is expanding its translational footprint, particularly for HPV/HBV-driven malignancies and actinic keratosis. APExBIO continues to provide high-quality, scalable KX2-391 for advanced research applications (KX2-391 dihydrochloride).